The impact of insurance status on the survival outcomes of patients with renal cell carcinoma

被引:8
|
作者
Li, Yan [1 ]
Zhu, Ming-Xi [2 ]
Zhang, Bing [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 4, Dept Anesthesiol, Yiyuan St 37, Harbin, Peoples R China
[2] Hainan Med Univ, Sch Basic Med & Life Sci, Dept Anat, Haikou, Hainan, Peoples R China
关键词
Adult; cancer-specific survival (CSS); renal cell carcinoma (RCC); Surveillance; Epidemiology and End Results database (SEER database); insurance status; HEALTH-INSURANCE; CANCER STAGE; ASSOCIATION; ADULTS; DIAGNOSIS; MORTALITY; RISK; CARE;
D O I
10.21037/tau-20-1045
中图分类号
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
摘要
Background: The impact of insurance status on renal cell carcinoma (RCC) patient survival is unclear. In this study, we investigated the effects of insurance status on the survival outcomes of RCC patients in the United States of America. Methods: Data of patients diagnosed with RCC between 2007 and 2014 were obtained from the Surveillance, Epidemiology and End Results (SEER) database, a large national database including statistics on cancer patients. The Kaplan-Meier method and Cox regression analysis were used to determine the influence of insurance status on cancer-specific survival (CSS). Results: A total of 30,951 eligible RCC patients were identified. Of these patients, 25,493 (82.37%) were insured, 3,959 (12.79%) had any Medicaid coverage, and 1,499 (4.84%) were uninsured. Kaplan-Meier analysis revealed that insurance status was associated with better CCS (P<0.001). The 5-year CSS rates of patients with insurance, any Medicaid, and no insurance were 88.3%, 82.6%, and 82.7%, respectively. Multivariate Cox regression analysis showed that patients with any Medicaid had poorer CSS than insured patients [hazard ratio (HR), 1.222; 95% confidence interval (CI), 1.100-1.357]. Stratified analysis revealed that at localized tumor stage and at regional tumor stage or among white patients, any Medicaid insurance was an independent predictor of an unfavorable survival outcome. Conclusions: Among the RCC patients in this study, individuals with insurance experienced improved CSS while individuals with any Medicaid tended to suffer worse survival outcomes.
引用
收藏
页码:1678 / 1690
页数:13
相关论文
共 50 条
  • [21] Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma
    Harun Fajkovic
    Shahrokh F. Shariat
    Tobias Klatte
    Mihai Dorin Vartolomei
    Ilaria Lucca
    Aurélie Mbeutcha
    Morgan Rouprêt
    Alberto Briganti
    Pierre I. Karakiewicz
    Vitaly Margulis
    Michael Rink
    Mesut Remzi
    Christian Seitz
    Karim Bensalah
    Romain Mathieu
    World Journal of Urology, 2016, 34 : 1411 - 1419
  • [22] Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
    Lalani, Aly-Khan A.
    McKay, Rana R.
    Lin, Xun
    Simantov, Ronit
    Kaymakcalan, Marina D.
    Choueiri, Toni K.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : 724 - 732
  • [23] Effect of Metformin Use on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma
    Hamieh, Lana
    McKay, Rana R.
    Lin, Xun
    Moreira, Raphael B.
    Simantov, Ronit
    Choueiri, Toni K.
    CLINICAL GENITOURINARY CANCER, 2017, 15 (02) : 221 - 229
  • [24] Angiotensin System Inhibitors and Survival Outcomes in Patients with Metastatic Renal Cell Carcinoma
    McKay, Rana R.
    Rodriguez, Gustavo E.
    Lin, Xun
    Kaymakcalan, Marina D.
    Hamnvik, Ole-Petter R.
    Sabbisetti, Venkata S.
    Bhatt, Rupal S.
    Simantov, Ronit
    Choueiri, Toni K.
    CLINICAL CANCER RESEARCH, 2015, 21 (11) : 2471 - 2479
  • [25] Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
    Alexandr Poprach
    Igor Kiss
    Michal Stanik
    Tamara Barusova
    Lenka Pospisilova
    Ondrej Fiala
    Jindrich Kopecky
    Igor Richter
    Bohuslav Melichar
    Hana Studentova
    Radek Lakomy
    Milos Holanek
    Aneta Rozsypalova
    Anezka Zemanková
    Marek Svoboda
    Tomas Buchler
    Targeted Oncology, 2023, 18 : 893 - 903
  • [26] Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
    Poprach, Alexandr
    Kiss, Igor
    Stanik, Michal
    Barusova, Tamara
    Pospisilova, Lenka
    Fiala, Ondrej
    Kopecky, Jindrich
    Richter, Igor
    Melichar, Bohuslav
    Studentova, Hana
    Lakomy, Radek
    Holanek, Milos
    Rozsypalova, Aneta
    Zemankova, Anezka
    Svoboda, Marek
    Buchler, Tomas
    TARGETED ONCOLOGY, 2023, 18 (06) : 893 - 903
  • [27] Impact of oncological versus nononcological on survival outcomes in African Americans with renal cell carcinoma
    Meagher, Margaret Frances
    Bradshaw, Aaron
    Patil, Dattatraya H.
    Saito, Kazutaka
    Cotta, Brittney
    Yasuda, Yosuke
    Eldefrawy, Ahmed
    Fujii, Yasuhisa
    Master, Viraj A.
    Derweesh, Ithaar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] The impact of race and insurance status on survival of prostate cancer patients
    Hew, Trevanne Rose Matthews
    Hew, Jason Desmond
    Chhatrala, Hardik Satish
    Tfirn, Ian
    Kadakia, Meet
    Gautam, Shiva
    Pham, Dat C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [29] The Impact of Preoperative Nutritional Status on the Survival of Patients With Esophageal Squamous Cell Carcinoma
    Chen, Shao-bin
    Liu, Di-tian
    Chen, Yu-ping
    FRONTIERS IN SURGERY, 2021, 8
  • [30] THE IMPACT OF FACILITY TYPE AND VOLUME ON SURVIVAL IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
    Elshabrawy, Ahmed
    Wang, Hanzhang
    Oelsen, James
    Liss, Michael
    Kaushik, Dharam
    Pruthi, Deepak
    Ramamurthy, Chethan
    Mansour, Ahmed M.
    JOURNAL OF UROLOGY, 2020, 203 : E916 - E917